September 10th, 2024 – INCATE, the INCubator for Antibacterial Therapies in Europe, is pleased to announce that Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics, has extended its partnership, which started in 2021, until 2027.

“This is excellent news for INCATE and the and the broader antimicrobial resistance (AMR) community,” said Christoph Dehio, Director of NCCR Antiresist and Board Member of INCATE. “Roche has been a key partner to INCATE since its inception in 2021. They also play a vital role in helping INCATE select the most promising early-stage candidates to address this critical challenge.”

“Extending our partnership with INCATE aligns perfectly with Roche’s mission to pursue scientific excellence to discover and develop medicines and diagnostics for the world’s most pressing healthcare challenges,” said Rusudan Okujava, Principal Scientist in Infectious Diseases Discovery, Roche Pharma Research and Early Development. “We are committed to supporting the development of new antibacterial treatments that have the potential to save lives and improve global public health outcomes.”

Antimicrobial resistance poses a significant threat to global health, with millions of lives at risk due to the diminishing efficacy of existing antibiotics. Through this extended collaboration, Roche and INCATE will continue to support innovators globally to develop new product candidates and technology platforms that can address this major challenge.

The unique INCATE support model has proven value for early stage ventures and will continue to expand to new geographies and deepen the ties with existing and new partners. INCATE is looking forward to supporting more innovators in their fight against drug-resistant bacterial infection.

About INCATE 

INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel are the academic founding members of INCATE with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, Roche, Shionogi and MSD as well as other organizations, funders and investors, INCATE want to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.

For more information please contact:
helena.costa.pereira@incate.net or +49 176 46172549
www.incate.net
Linkedin: @INCATE
X (former Twitter): @INCATEurope